A study showed that when male mice treated with aromatase inhibitor, AR expression was increased compared to the control mice [94], suggesting that post-menopausal women may express more AR than pre-menopausal women or it could be that women after menopause express more aromatase for the production of E2, which may lead to breast cancers [95]. Here, CYP19A1 is linked to breast carcinoma.